Company / R&D Expense
Emergent BioSolutions Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$53.2M
FY2025
5-year range
$53.2M / $235.2M
FY2021-FY2025
Trend
-24.8%
vs FY2024
Sector context
#178 of 210
Health Care
What the data says
Emergent BioSolutions Inc.'s r&d expense of $53M is lower than 85% of companies in the Health Care sector (FY2025). R&D Expense has declined for 4 consecutive years, from $235M in FY2021 to $53M in FY2025.
Based on SEC 10-K filings.
$53M in FY2025 with a 5-year CAGR of -25.7%.
Declined from $111M to $53M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -34.4%
- 5-Year CAGR
- -25.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 210This company $53.2M Sector average $644.1M
▼
-91.7% below sector average
Key checks
Key Insights
- Emergent BioSolutions Inc.'s r&d expense has declined for 4 consecutive years.
- 5-year CAGR of -25.7%, indicating a declining trend.
- In FY2025, r&d expense decreased 24.8% year-over-year.
- Ranks #178 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $53.2M | -24.8% |
| FY2024 | $70.7M | -36.5% |
| FY2023 | $111.4M | -40.8% |
| FY2022 | $188.3M | -19.9% |
| FY2021 | $235.2M | +0.3% |
| FY2020 | $234.5M | +3.7% |
| FY2019 | $226.2M | +111.6% |
| FY2018 | $106.9M | +9.8% |
| FY2017 | $97.4M | -8.9% |
| FY2016 | $106.9M | -10.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026